Want to see VCNX full AI Analyst Report?
Top Page
Vaccinex
(OTC:VCNX)
Select Model
Select Model
Rating:44Neutral
Price Target:
$0.96
▼(-18.64% Downside)
Action:Reiterated
Date:07/21/26
The score is primarily held down by weak financial performance—persistent losses, continued cash burn, and negative equity with rising debt. Technicals add pressure with the stock trading below all major moving averages and only modest momentum signals. Valuation contributes slightly but is constrained by negative earnings and no dividend data.
Positive Factors
Revenue Acceleration
2025 revenue growth of ~249% to ~$2.10M demonstrates accelerating top-line traction for a clinical-stage biotechs' programs. Sustained revenue expansion can fund clinical R&D, improve bargaining position for partners, and enable operating leverage if growth persists.
Negative Factors
Negative Equity
Negative shareholders' equity (~ -$7.59M) signals a capital deficit and weak balance-sheet buffer. This reduces financial flexibility, increases reliance on external financing, and elevates solvency and restructuring risk if operating losses continue.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Acceleration
2025 revenue growth of ~249% to ~$2.10M demonstrates accelerating top-line traction for a clinical-stage biotechs' programs. Sustained revenue expansion can fund clinical R&D, improve bargaining position for partners, and enable operating leverage if growth persists.
Read all positive factors
Vaccinex (VCNX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.65M
Dividend YieldN/A
Average Volume (3M)1.22K
Price to Earnings (P/E)―
Beta (1Y)2.15
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees25
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-10.48
Shares Outstanding2,676,637
10 Day Avg. Volume776
30 Day Avg. Volume1,224
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.38
Price to Sales (P/S)1.38
P/FCF Ratio-0.45
Enterprise Value/Market Cap0.62
Enterprise Value/Revenue2.74
Enterprise Value/Gross Profit2.87
Enterprise Value/Ebitda-0.09
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Vaccinex Business Overview & Revenue Model
Company Description
Vaccinex, Inc. is a biotechnology firm operating in the clinical stage, dedicated to identifying and developing specialized biological therapies. Its core mission is to address serious medical conditions and diseases that currently lack adequate t...
How the Company Makes Money
null...
Vaccinex Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 601.00K | 2.10M | 601.00K | 570.00K | 100.00K | 900.00K |
| Gross Profit | 574.00K | 2.06M | 601.00K | 570.00K | 68.00K | 731.00K |
| EBITDA | -18.51M | -5.20M | -18.54M | -19.75M | -19.61M | -21.40M |
| Net Income | -18.63M | -5.26M | -18.63M | -20.25M | -19.72M | -22.38M |
Balance Sheet | ||||||
| Total Assets | 2.60M | 1.80M | 2.60M | 3.63M | 7.98M | 9.84M |
| Cash, Cash Equivalents and Short-Term Investments | 1.11M | 140.00K | 1.11M | 1.53M | 6.39M | 8.59M |
| Total Debt | 25.00K | 5.52M | 25.00K | 247.00K | 485.00K | 390.00K |
| Total Liabilities | 5.08M | 9.39M | 5.08M | 5.94M | 2.78M | 2.43M |
| Stockholders Equity | -2.49M | -7.59M | -2.49M | -2.31M | 5.19M | 7.41M |
Cash Flow | ||||||
| Free Cash Flow | -16.21M | -6.46M | -16.21M | -17.30M | -19.17M | -25.33M |
| Operating Cash Flow | -16.19M | -6.45M | -16.19M | -17.23M | -19.07M | -25.30M |
| Investing Cash Flow | -22.00K | -9.00K | -22.00K | -67.00K | -99.00K | -32.00K |
| Financing Cash Flow | 15.78M | 5.49M | 15.78M | 12.45M | 16.98M | 23.32M |
Vaccinex Technical Analysis
Negative
1.18
Price Trends
1.06
Negative
1.05
Negative
0.97
Positive
Market Momentum
-0.01
Positive
44.84
Neutral
42.32
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VCNX, the sentiment is Negative. The current price of 1.18 is above the 20-day moving average (MA) of 1.11, above the 50-day MA of 1.06, and above the 200-day MA of 0.97, indicating a neutral trend. The MACD of -0.01 indicates Positive momentum. The RSI at 44.84 is Neutral, neither overbought nor oversold. The STOCH value of 42.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VCNX.
Vaccinex Risk Analysis
Vaccinex disclosed 49 risk factors in its most recent earnings report. Vaccinex reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Vaccinex Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $4.54M | -0.16 | -107.66% | ― | ― | 95.51% | |
44 Neutral | $2.65M | -0.42 | 1406.28% | ― | ― | ― | |
44 Neutral | $10.13M | -0.09 | -178.29% | ― | ― | 87.76% | |
43 Neutral | $2.19M | -0.06 | -251.51% | ― | -100.00% | 89.96% | |
40 Underperform | $14.19M | -0.05 | -901.32% | ― | ― | -152.00% |
* Healthcare Sector Average
VCNX
Vaccinex
0.99
0.29
41.43%
TOVX
Theriva Biologics
0.23
-0.19
-45.39%
GTBP
GT Biopharma
0.32
-1.42
-81.61%
REVB
Revelation Biosciences
1.13
-8.39
-88.13%
CERO
CERo Therapeutics Holdings
0.01
-7.99
-99.88%
AZTR
Azitra Inc
0.14
-0.92
-86.78%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.